Monoclonal antibody CBB 1 injection - Changchun BCHT Biotechnology
Alternative Names: CBB 1 injection; mAb CBB 1Latest Information Update: 16 Aug 2024
At a glance
- Originator Changchun BCHT Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rabies
Most Recent Events
- 31 Jul 2024 Changchun BCHT Biotechnology plans a phase II trial for Rabies (Combination therapy) in China (IM, Injection) in July 2024 (NCT06548139)
- 30 Apr 2023 Preclinical trials in Rabies in China (IM)
- 30 Apr 2023 Changchun BCHT Biotechnology plans phase I clinical trial in Rabies (Prevention, In adults) in China (IM) (NCT05832073)